Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Multiple Modes of Ryanodine Receptor 2 Inhibition by Flecainide

D. Mehra, M. S. Imtiaz, D. F. van Helden, B. C. Knollmann and D. R. Laver
Molecular Pharmacology December 2014, 86 (6) 696-706; DOI: https://doi.org/10.1124/mol.114.094623
D. Mehra
School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.M., M.S.I., D.F.v.H., D.R.L.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee (B.C.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. S. Imtiaz
School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.M., M.S.I., D.F.v.H., D.R.L.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee (B.C.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. F. van Helden
School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.M., M.S.I., D.F.v.H., D.R.L.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee (B.C.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. C. Knollmann
School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.M., M.S.I., D.F.v.H., D.R.L.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee (B.C.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. R. Laver
School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.M., M.S.I., D.F.v.H., D.R.L.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee (B.C.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 86 no. 6 696-706
DOI 
https://doi.org/10.1124/mol.114.094623
PubMed 
25274603

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received July 7, 2014
  • Accepted September 24, 2014
  • Published online October 29, 2014.

Article Versions

  • Earlier version (October 1, 2014 - 09:18).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. D. Mehra,
  2. M. S. Imtiaz,
  3. D. F. van Helden,
  4. B. C. Knollmann, and
  5. D. R. Laver
  1. School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.M., M.S.I., D.F.v.H., D.R.L.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee (B.C.K.)
  1. Address correspondence to:
    Dr. Derek Laver, School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia. E-mail: Derek.Laver{at}newcastle.edu.au
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: October 2014 to January 2023

AbstractFullPdf
Oct 20142326163
Nov 20142603050
Dec 2014811825
Jan 2015572020
Feb 2015331717
Mar 2015411311
Apr 201522810
May 201541816
Jun 20152643
Jul 20152143
Aug 20152934
Sep 20152332
Oct 201528159
Nov 2015241319
Dec 2015171513
Jan 2016181115
Feb 201612106
Mar 2016141515
Apr 201681615
May 201615127
Jun 20161989
Jul 2016161012
Aug 201620164
Sep 2016115911
Oct 201625211
Nov 20167457
Dec 201645517
Jan 201716017
Feb 201775012
Mar 201706319
Apr 201715711
May 201732616
Jun 20171258
Jul 20172143
Aug 20175143
Sep 201711498
Oct 201721442
Nov 20173286
Dec 20173318
Jan 20181298
Feb 201822210
Mar 20181227
Apr 20185233
May 20181215
Jun 20181202
Jul 20182144
Aug 20180174
Sep 20182155
Oct 20186247
Nov 20181468
Dec 20180430
Jan 20192369
Feb 20192386
Mar 20191228
Apr 20190185
May 201901816
Jun 201911010
Jul 20192119
Aug 20190148
Sep 20191914
Oct 201902929
Nov 20191114
Dec 20193117
Jan 20202811
Feb 20200910
Mar 2020097
Apr 2020188
May 20200516
Jun 202011511
Jul 20200125
Aug 2020157
Sep 20202721
Oct 202001417
Nov 20201925
Dec 20203152
Jan 20211912
Feb 20211825
Mar 20211654
Apr 20211310
May 20212932
Jun 2021825
Jul 2021714
Aug 20211623
Sep 20211031
Oct 20212544
Nov 20211753
Dec 20211822
Jan 20223032
Feb 20223110
Mar 20221723
Apr 20221214
May 20221935
Jun 20222021
Jul 20221124
Aug 20221912
Sep 20221221
Oct 20221234
Nov 20221510
Dec 20222120
Jan 20232110

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 86 (6)
Molecular Pharmacology
Vol. 86, Issue 6
1 Dec 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Multiple Modes of Ryanodine Receptor 2 Inhibition by Flecainide
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Flecainide Inhibition of RyR2

D. Mehra, M. S. Imtiaz, D. F. van Helden, B. C. Knollmann and D. R. Laver
Molecular Pharmacology December 1, 2014, 86 (6) 696-706; DOI: https://doi.org/10.1124/mol.114.094623

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Flecainide Inhibition of RyR2

D. Mehra, M. S. Imtiaz, D. F. van Helden, B. C. Knollmann and D. R. Laver
Molecular Pharmacology December 1, 2014, 86 (6) 696-706; DOI: https://doi.org/10.1124/mol.114.094623
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics